The response of the myocardium to an ischaemic insult is regulated by two highly homologous protein kinase C (PKC) isozymes, d and 1PKC. Here, we determined the spatial and temporal relationships between these two isozymes in the context of ischaemia/reperfusion (I/R) and ischaemic preconditioning (IPC) to better understand their roles in cardioprotection.
Introduction
Myocardial ischaemia and reperfusion (I/R)-induced damage is associated with both apoptotic and necrotic cell death. 1 We have shown this to be dependent on translocation of delta protein kinase C (dPKC) to cardiac mitochondria where it inhibits mitochondrial function. 2 -4 Inhibition of dPKC with the selective peptide inhibitor, dV 1 -1 , protects the heart from ischaemic injury. 4, 5 Ischaemic preconditioning (IPC) observed in animals and humans 6 -8 protects the heart from reperfusion injury by activating pro-survival kinases, 9 -11 preventing apoptosis 12, 13 and necrosis 2, 4 preserving mitochondrial function, 14, 15 and reducing ROS generation. 16 Many of these effects are afforded, at least in part, through activation and translocation of 1PKC to cardiac mitochondria, 17 -20 resulting in diminished apoptosis and necrosis. 12, 21 Interestingly, activation of dPKC is also required for both opioid 22 and IPC-mediated protection. 23, 24 We showed that activation of dPKC is cardioprotective provided there is sufficient time allowed for 1PKC activation. 25 Furthermore, 1PKC is activated by ROS during IPC, 26 whereas dPKC plays a role in ROS generation. 27 Therefore, although both PKC isozymes play a role in IPC, the mechanism by which the pro-survival kinase (1PKC) and the pro-death kinase (dPKC) interact is not known. Here, we present evidence of a novel mechanism in which the proteasome alters the ratio between dPKC and 1PKC, thereby regulating myocardial viability following I/R.
Methods

Materials
All antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Lactacystin, LLVY-AMC, epoxomycin, and MG-132 were from Biomol (Plymouth Meeting, PA 
Isolated perfused rat heart model and measurement of tissue necrosis
All procedures were carried out as described. 2 All animal protocols were approved by the Institutional Animal Care and Use Committee of Stanford University.
Cellular fractionation and western blotting
Isolated hearts were homogenized in 210 mM mannitol, 70 mM sucrose, 1 mM EDTA, and 5 mM MOPS, pH ¼ 7.4. After filtering through cheesecloth and a 5 min centrifugation at 800Âg, the supernatant was centrifuged (10 000Âg; 10 min) to obtain the mitochondrial pellet and the cytosolic extract (supernatant). This technique provides a mitochondrial fraction with only traces of sarcolemmal and plasma membrane contamination. 30 Western blot analysis used polyclonal 1PKC, dPKC, p-Akt, Akt, and cytochrome c antibodies, was normalized to ANT (mitochondria) and GAPDH (total and cytosolic homogenates) and was expressed as percent control.
Assay of proteasome activity
Chymotrypsin-like activity of the proteasome was assayed using the fluorogenic peptide Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (25 mM, LLVY-MCA) in a microtiter plate (50 mg protein) with 200 ml of 10 mM MOPS, pH 7.4. Assays were carried out in the absence and presence of 2.5 mM ATP and 5.0 mM Mg 2þ with the difference attributed to ATP-dependent proteasome activity. The rate of fluorescent product formation was measured with excitation and emission wavelengths of 350 and 440 nm, respectively. In order to block proteasome activity during the experimental protocol, 2.0 mM lactacystin was perfused during the preconditioning protocol and the first 10 min of reperfusion.
Slot blot analysis of cellular misfolded proteins
Heart tissue homogenate (25 mg protein) was normalized and slot blotted onto PVDF membrane (Millipore, Bedford, MA, USA) and membranes were washed three times with 0.05% Tween 20, 10 mM Tris, pH 7.5, 100 mM NaCl (T-TBS) and blocked in T-TBS þ 5% milk. After 4 h of incubation with an anti-soluble oligomer antibody (Biosource International, Camarillo, CA), an antibody that recognizes misfolded proteins, 31 proteins were visualized as in the western blot analysis. Sample loading was normalized by Ponceau staining.
Analysis of cellular ATP levels
ATP determination was carried out using the Molecular Probes luciferasebased ATP determination kit (Kit# A22066). In brief, 100 mg of protein was incubated in a 96-well plate with 50 mM luciferin and 1.25 mg/mL luciferase in a Tris-based 1X reaction buffer containing DTT. ATP was measured after 5 min using a luminometer (560 nm at room temperature) using a standard curve of known ATP concentrations.
Statistics
Data are represented as the mean + SE, and significance was determined by one-way analysis of variance with a post-hoc Tukey test or a two-tailed t-test.
Results
IPC diminishes dPKC at the mitochondria and increases 1PKC translocation
Since the mitochondria are critical sites of regulation by d and 1PKC during I/R, 2 -6,10,16,19 -22 we first determined the levels of d and 1PKC
in this fraction. Thirty minutes of ischaemia and 60 min reperfusion (I 30 /R 60 ) ( Figure 1A ) resulted in accumulation of dPKC (6-fold; P , 0.001; n ¼ 5) and 1PKC (9-fold; P , 0.05; n ¼ 5) at the mitochondria ( Figure 1B) . However, after IPC, I/R-induced dPKC accumulation at the mitochondrial fraction was largely prevented, whereas 1PKC translocation increased 2-fold higher than hearts that were not preconditioned (P , 0.01; n ¼ 5) ( Figure 1B) . Interestingly, IPC resulted in a seven-fold greater increase in 1PKC at cardiac mitochondria relative to dPKC ( Figure 1B) . The IPC stimulus alone (without subsequent I 30 /R 60 ) ( Figure 1C 
Total cellular levels of dPKC are greatly diminished by IPC
To determine whether the changes in the mitochondrial levels of d and 1PKC reflect changes in the cellular levels of these kinases, we next determined the levels of both 1PKC and dPKC in total cardiac extracts. I 30 /R 60 alone did not affect the overall levels of dPKC or 1PKC vs. normoxia (N; n ¼ 4; Figure 2 ). However, after IPC followed by ischaemia, dPKC levels decreased by 33% (vs. N, P , 0.05; n ¼ 4), whereas 1PKC levels did not. Therefore, the reduction in dPKC translocation to the mitochondria ( Figure 1B ) appears to be associated with diminished protein levels, and this effect is selective and does not seem to affect 1PKC translocation.
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3.3 IPC-induced proteasomal degradation of dPKC diminished its translocation to cardiac mitochondria with a concurrent increase in 1PKC translocation to this fraction dPKC has been shown to be degraded by the 26S proteasome. 29 Declines in ATP levels during ischaemia result in the disassembly of the 26S proteasome into the 20S form. 32 In contrast, IPC reduces ischaemia-mediated declines in ATP levels. 8, 33 We therefore determined whether the loss in dPKC levels following IPC prior to I/R relates to preservation of the 26S proteasome activity. ATP Mg 2þ -stimulated peptidase activity is a reflection of the relative level of the 26S proteasome. Ischaemia induced a 45% decline in ATP-dependent proteasomal activity ( Figure 3B ) that was associated with an 3-fold increase in the accumulation of misfolded proteins during reperfusion ( Figure 3C ). IPC prevented the Figure 2 Diminished mitochondrial levels of dPKC following IPC are due to decreased cellular levels of the isozyme. Hearts were hung in Langendorff mode and treated with the listed perfusion protocols in Figure 1 . Hearts were then removed, and homogenized, and the total homogenate was subjected to western blot analysis with antibodies against the proteins listed in the figure. Values were normalized to glyceraldehyde phosphate dehydrogenase (GAPDH), a cytosolic protein, and expressed as %N. I 30 R 60 had no significant effect on total levels of either dPKC or 1PKC. However, IPC before the global ischaemic event decreased the overall levels of dPKC by 80% (P , 0.05 vs. N), but not 1PKC levels. *P , 0.05 vs. Normoxia and ‡P , 0.05 vs. I 30 R 60 . Cellular dPKC and 1PKC levels were analysed by one-way analysis of variance with a post-hoc Tukey test. Chymotrypsin-like activity of the proteasome present in the cytoplasmic milieu was evaluated and the specific inhibitor MG-132 (20 mM) was utilized to ensure that measured activities were due to the proteasome (data not shown). The presence of unfolded proteins was evaluated using the slot blot technique with an anti-soluble oligomer antibody. Values representing ATP-dependent proteasome activity and misfolded proteins are presented as a percent of values obtained with samples from hearts exposed to 60 min of normoxic perfusion (N). Values represent the mean + standard deviation (n ¼ 4). (B) Ischaemia resulted in a 50% decline in ATP-dependent proteasome activity (P , 0.05 vs. N), which was completely reversed by IPC (P , 0.05 vs. I 30 ). The proteasome inhibitor, lactacystin (2 mM) and the specific 1PKC inhibitor (1mM 1V 1 -2 ) both significantly decreased the activity of the proteasome (P , 0.05 vs. I 30 R 60 þ IPC; n ¼ 4). (C ) I 30 R 60 resulted in an 3-fold increase in misfolded proteins which was prevented by IPC (P , 0.05; n ¼ 4). Treatment of hearts with lactacystin or 1V Misfolded protein accumulation and proteasome activity were analysed by one-way analysis of variance with a post-hoc Tukey test. Figure 3D , proteasome activity was analysed by Student's t-test.
Figure 4
Inhibition of the proteasome restores dPKC cellular and mitochondrial levels in IPC hearts with a resultant decrease in 1PKC levels.
(A) Hearts were hung in Langendorff mode and treated with the above-mentioned perfusion protocols. Hearts were then removed, homogenized, and the total homogenate and mitochondrial fractions were subjected to western blot analysis with antibodies against the proteins listed in the figure. Values were normalized to GAPDH (total homogenate) or ANT (mitochondrial fraction) and expressed as % I 30 R 60 . IPC before prolonged ischaemia reduced total levels of dPKC by 80% (P , 0.05 vs. I 30 R 60 ). Inhibition of the proteasome with 2 mM lactacystin blocked dPKC degradation (P , 0.05 vs. I 30 R 60 þ IPC). Similar to Figure 2 , IPC before prolonged ischaemia did not significantly change overall levels of 1PKC. However, inhibition of the proteasome increased 1PKC levels by 2-folds (P , 0.05 vs. I 30 R 60 ). Inhibition of 1PKC activity with 1V 1 -2 did not significantly change the overall levels of either d or 1PKC isozymes (data not shown). (B) As in Figure 2 , IPC before I 30 R 60 decreased levels of dPKC at mitochondria by 60% (P , 0.05 vs. I 30 R 60 ). This was completely prevented in hearts treated with 2 mM lactacystin and 1 mM 1V Ischaemic preconditioning and proteasomal regulation of dPKC ischaemia-mediated declines in proteasomal activity and reduced the levels of misfolded proteins (Figure 3B and C; P , 0.05; n ¼ 4). Furthermore, ATP levels correlated with proteasomal activity; ATP levels diminished during ischaemia/reperfusion and IPC significantly prevented this decline ( Figure 3D ). To determine if IPC increases proteasomal degradation of dPKC, we perfused the proteasome inhibitor, lactacystin (2 mM), during IPC and the first 10 min of reperfusion ( Figure 3A) . Lactacystin significantly blocked the activity of the proteasome (75%; P , 0.01; n ¼ 4; Figure 3B ) and increased the levels of misfolded proteins by 7-fold ( Figure 3C ). In agreement with our findings in Figure 2 , IPC reduced post-reperfusion cellular levels of dPKC by 80% (P , 0.01; n ¼ 4; Figure 4A ). However, inhibition of the proteasome with lactacystin prevented the loss of dPKC after IPC and I 30 R 60 ( Figure 4A ). Although lactacystin treatment did not affect the levels of 1PKC relative to IPC, the ratio of 1PKC to dPKC decreased due to elevated levels of dPKC.
Since lactacystin-mediated inhibition of the proteasome during IPC prevented dPKC degradation, it may promote translocation of dPKC to cardiac mitochondria. Indeed, lactacystin treatment completely blocked IPC-induced reductions in dPKC levels, restoring mitochondrial dPKC to levels obtained after I 30 /R 60 alone ( Figure 4B) . Interestingly, in contrast to the effects of proteasome inhibition on total 1PKC levels, mitochondrial levels of 1PKC were reduced by 50% in the presence of lactacystin ( Figure 4C ). These data suggest that IPC inversely affects the ratios of these two PKC isozymes at cardiac mitochondria following I/R likely through the regulation of proteasome activity. Additionally, lactacystin abolished IPC-mediated protection of ATP levels following ischaemia/reperfusion ( Figure 3D) .
We determined whether 1PKC indirectly downregulates dPKC by protecting proteasomal function during IPC. To this end, we perfused the specific 1PKC inhibitor, 1V 1 -2 34 ( Figure 3A) and found an 70% inhibition of proteasomal activity, an effect that was similar to that obtained by lactacystin ( Figure 3B) , and resulted in a corresponding increase in cellular misfolded proteins ( Figure 3C ). Similar to lactacystin, 1V 1 -2 treatment significantly decreased 1PKC levels at cardiac mitochondria (71% vs. IPC), and restored dPKC levels in this fraction (P , 0.05; n ¼ 7) (Figure 4B and C ). Perfusion with a specific 1PKC activator, c1RACK, before ischaemia mimicked the IPC-mediated protective effect on proteasomal activity and prevented the loss in proteasomal activity seen during I/R ( Figure 3E) . This is likely an indirect effect, since 1PKC was not found to associate with the proteasome following c1RACK treatment (data not shown).
Inhibition of the proteasome prevents Akt activation and increases release of cytochrome c during IPC
IPC activates the pro-survival kinases, Akt, and ERK1/2 and blocks cytochrome c release during reperfusion. 10, 15, 35 In contrast, dPKC decreases Akt activation and increases cytochrome c release during I/R. 2 Here we found that IPC significantly blocked I 30 /R 60 mediated release of mitochondrial cytochrome c into the cytosol (60%; P , 0.05; n ¼ 4) ( Figure 5A ) and inhibition of the proteasome with lactacystin restored cytochrome c release to the levels seen during I 30 /R 60 (P , 0.05). Treatment of non-ischaemic hearts with either lactacystin or 1V 1 -2 did not cause significant release of cytochrome c into the cytosol ( Figure 5B) . Additionally, IPC significantly increased the phosphorylation of the pro-survival kinase, Akt, over I 30 /R 60 levels (300%), and this was abolished by lactacystin treatment ( Figure 5C ). Li et al. showed that activation of dPKC reduces Akt phosphorylation whereas inhibition of dPKC increased Akt phosphorylation. They suggested that dPKC-mediated inhibition of Akt proceeds through increased association of protein phosphatase 2a. 36 Neither IPC nor lactacystin treatments significantly changed the phosphorylation levels of ERK-1/2 (not shown), consistent with the findings of other studies.
37,38
Inhibition of the proteasome during IPC increases tissue injury
Since pharmacological inhibition of the proteasome during IPC restored the apoptotic phenotype, we determined if tissue injury is altered by proteasome inhibition. As reported, IPC decreased both creatine phosphokinase (CPK) release and tetrazolium tetrachloride (TTC) staining of the myocardium by 70 and 60%, respectively ( Figure 6A and B) and Lactacystin reversed the benefits of IPC-mediated protection. As we found before in isolated myocytes, 28 in addition to the effects of 1V 1 -2 on proteasomal function and dPKC translocation, inhibition of 1PKC also completely reversed the protective effects of IPC on the myocardium ( Figure 6A and B) . Finally, to confirm the effects of lactacystin, we utilized another highly selective inhibitor of the proteasome, epoxomicin. Similar to lactacystin, inhibition of the proteasome with epoxomicin (2 mM) abolished the cardioprotective effects of IPC (data not shown).
Discussion
Our data suggest that IPC-induced decreases in mitochondrial dPKC levels are due to decreased total levels of dPKC. We also show that IPC prevents ischaemia-mediated declines in the 26S ATP-dependant proteasomal activity and that this is associated with diminished accumulation of cellular misfolded proteins. Ischaemia-mediated declines in forebrain ATP levels promote dissociation of the 26S proteasome (the form responsible for dPKC degradation 29 ) to the 20S proteasome. 32 During I/R, (in the absence of preconditioning) the significant decrease in ATPdependent proteasomal activity is therefore likely due to decreased ATP levels within the cells. Indeed, as has been shown before, 4, 39 and here in an ex vivo model of ischaemia/reperfusion, ATP levels significantly declined during ischaemia/reperfusion and IPC significantly prevented this decline ( Figure 3D ). Alternatively, modifications by lipid peroxidation products and accumulation of oxidized proteins during I/R may also act as inhibitors of proteasomal function. 40 Inhibition of the proteasome with lactacystin or epoxomicin blocked the protective effects of IPC. Additionally, lactacystin treatment elevated dPKC cellular and mitochondrial levels, and promoted cytochrome c release. dPKC is ubiquitinated within 30 min of activation 41 and direct inhibition of the 26S proteasome with Bortezomib, a highly selective proteasome inhibitor currently in clinical use for the treatment of haematological cancers, increases mitochondrial ROS generation, cytochrome c release, and apoptosis associated with mitochondrial accumulation of dPKC. 29, 42 We suggest that since IPC and 1PKC activation slow ATP depletion during prolonged ischaemia 8, 43 and dPKC is likely activated by the IPC stimulus ( Figure 1C ) 3 the 26S proteasomal activity is maintained leading to the degradation of pro-apoptotic and pro-necrotic, dPKC, 2, 4 thereby conferring cardiac protection. Although the most likely explanation for the decrease in dPKC levels in the mitochondria is a decrease in total level of this isozyme in the cells (due to its increased degradation by the proteasome), we cannot exclude the possibility that decreased affinity of the binding site for dPKC in the mitochondria and post-translational modifications of the enzyme or its binding proteins also contribute to dPKC declined levels and therefore activity in the mitochondria. We have previously shown that accumulation of dPKC at cardiac mitochondria increases PDH phosphorylation and the inhibitor dV 1 -1 prevents this. 3 Additionally, we have shown that 1PKC is able to activate ALDH2 in hearts in the same in vivo model of I/R. 44 Therefore, we have already provided direct evidence in this model of I/R that increased levels of PKC isozymes in the mitochondrial fraction are associated with increased phosphorylation of target substrates and hence reflect increased catalytic activity of these isozymes.
In addition to the protection afforded by degrading dPKC, increased 1PKC accumulation at cardiac mitochondria is also likely to confer protection. 1PKC translocates to mitochondria, 16,19 -22 where it prevents opening of the mitochondrial permeability transition pore, 19, 45 opens kATP channels, 9 forms signalling complexes with MAPK, 9 retards the reduction in cellular ATP levels, 46 interacts with the electron transport chain, 47 and augments mitochondrial function 39 all of which contribute to cardioprotection. Since the relative level of 1PKC at the mitochondria during reperfusion in the absence of the IPC stimulus is similar to dPKC levels, 1PKC-mediated cardioprotection may be masked by the pro-apoptotic and pro-necrotic effects of dPKC during reperfusion. Administration of the 1PKC activator, c1RACK, prior to ischaemia, which mimics IPC and protects mitochondrial function 39 prevented ischaemia-mediated declines in proteasome activity. Although recent studies suggest that kinases may regulate proteasome function directly, 48 we did not find any physical association between 1PKC and the proteasome. In summary, activated dPKC has two potential fates that appear to depend on the metabolic state of the cell. If mitochondrial function, cellular energy status, and the integrity of the 26S proteasome are maintained, dPKC is efficiently degraded. In contrast, if mitochondrial function and ATP production are compromised, the ATP-dependent 26S proteasome activity is diminished, resulting in increased levels of activated dPKC at the mitochondria, where it participates in the induction of cell death. The proteasome can therefore be viewed as a sensor of cellular viability, determining the ratio of pro-apoptotic dPKC and pro-survival 1PKC at the mitochondria and thus the ultimate fate of the cell. We propose the following mechanism. The decrease in ATP levels seen during I/R ( Figure 3D ) and increased generation of reactive oxygen species, will diminish 26S proteasome activity. 40 dPKC is activated by ROS 4 and also during the early stages of reperfusion, resulting in its accumulation at cardiac mitochondria ( Figure 1 ).
3
Because the activity of the proteasome is diminished (Figure 3) , dPKC is not degraded, favouring its accumulation at cardiac mitochondria (Figure 4) , where it triggers pro-apoptotic cytochrome c release and inactivation of Akt ( Figure 5 ), leading to tissue injury ( Figure 6 ). In contrast, IPC is associated with a small burst of mitochondrial ROS during the trigger phase of IPC, which decreases ROS generation during the effector phase 49 and may also act as a stimulus for dPKC activation ( Figure 1C) . Diminished ROS generation and maintenance of cellular ATP levels ( Figure 3D ) result in protection of proteasomal function, 50 which leads to degradation of dPKC ( Figure 4A ). Since both 1PKC and dPKC accumulate at the mitochondria during I 30 R 60 ( Figure 1B ) and since 1PKC is not degraded during I 30 R 60 (Figure 2A) , degradation of dPKC during IPC tips the balance towards the accumulation of the pro-survival kinase, 1PKC, at cardiac mitochondria, thus protecting mitochondrial function and proteasomal activity thereby diminishing I/ R-mediated tissue injury.
Conflict of interest: D.M.-R. is the founder of KAI Pharmaceuticals. However, none of the work described in the study is based on or supported by the company. Figure 6 Inhibition of the proteasome reverses the IPCmediated protective effects on tissue injury. Hearts were hung in Langendorff mode and treated with the listed perfusion protocols. Tissue injury was determined by measuring the release of CPK into the cardiac effluent (total CPK units). Following removal, hearts were sliced and stained with TTC to differentiate between necrotic (stained white) and viable (stained red) tissue (% infarct). (A,B) Hearts subjected to I 30 R 60 showed an increase in both CPK release and myocardial infarction and both were blocked by IPC (reductions of 60% for CPK release and 40% for infarction, respectively). Perfusion of 2 mM lactacystin during the IPC protocol and for the first 10 min of reperfusion reversed this effect resulting in significantly higher levels of CPK release (P , 0.05 vs. I 30 R 60 þ IPC) and myocardial infarction (P , 0.05 vs. I 30 R 60 þ IPC). Similar to proteasome inhibition, 1PKC inhibition (1 mM 1V 
